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ABSTRACT 
Background: Controversy exists as to whether individuals with hyperten- 
sion without risk factors for atherosclerosis (eg, diabetes mellitus, dyslipide- 
mia, obesity) have elevated levels of cell adhesion molecules (CAMs). 
Objective: The aim of this study was to determine whether (1) levels of sol- 
uble CAMs (sCAMs) (soluble E-selectin [sE-selectin], soluble intercellular dhe- 
sion molecule-1 [sICAM-1], soluble vascular cell adhesion molecule-1 [sVCAM-1], 
and yon Willebrand factor [vWF]) are elevated in Taiwanese adults with uncom- 
plicated essential hypertension without other risk factors; (2) CAM levels 
increase with severity (stage) of hypertension; and (3) monotherapy with the 
angiotensin II-receptor blocker (ARB) irbesartan modulates CAM expression i
a subgroup of these patients. 
Methods: This observational, controlled pilot study was conducted at the 
Hypertension Clinic, Department of Internal Medicine, Kaohsiung Medical Uni- 
versity Hospital, Kaohsiung, Taiwan. Adult patients with uncomplicated es- 
sential hypertension without other risk factors (eg, diabetes mellitus, dyslipid- 
emia, obesity) and normotensive controls were eligible. Blood pressure (BP) 
was determined using 24-hour ambulatory BP monitoring (ABPM) in all partici- 
pants, and the staging of hypertension was classified based on criteria in The 
Seventh Report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure (normotensive, prehyper- 
tension, stage I hypertension, and stage II hypertension). The sCAM levels and 
*This study was presented in poster form at the American College of Cardiology Annual Scientific 
Session 2005, Orlando, Florida, March 6-9, 2005. 
Accepted for publication April 4, 2005. 
Reproduction in whole or part is not permitted. 
doi:l 0.1016/j.curtheres.2005.06.005 
0011-393X/05/$19.00 
Copyright © 2005 Excerpta Medica, Inc. 181 
CURRENT THERAPEUTIC ~ESEARCH 
24-hour ABPM were measured before and after 8 weeks of open-label irbesartan 
monotherapy in a subgroup of the patients with hypertension. Patients who 
had difficulty achieving the target BP values on irbesartan monotherapy were 
treated with combination therapy (2 or 3 antihypertensive agents); levels of 
sCAMs were not measured in these patients. Plasma levels of sE-selectin, the 
sCAMs, and vWF were measured using enzyme-linked immunosorbent assay. 
Results: The study comprised 61 patients with uncomplicated essential 
hypertension (33 men and 28 women; mean [SD] age, 51 [12] years) and 17 nor- 
motensive controls (11 men, 6 women; mean [SD] age, 52 [ 11] years). The mean 
(SD) dose of irbesartan was 243 (63) mg. Hypertensive patients had significant- 
ly higher circulating levels of sICAM-1 compared with normotensive controls 
(P -- 0.009). No significant differences in levels of sVCAM-1, sE-selectin, or vWF 
were found between hypertensive patients and controls. The mean slCAM-1 
level was significantly higher in the prehypertensive patients compared with 
normotensive controls (P-- 0.03). The mean sE-selectin level was significantly 
higher in the patients with stage I hypertension compared with the prehyper- 
tensive group (P = 0.01). The 18 patients given 8 weeks of irbesartan monother- 
apy showed a significant decrease from baseline in systolic and diastolic BP 
(both, P-- 0.001) and sE-selectin (P = 0.006), but not in sVCAM-1 or sICAM. Forty- 
three patients did not reach target BP on irbesartan monotherapy and thus 
were treated with combination therapy. 
Conclusions: Based on the results of this observational, controlled pilot 
study in Taiwanese patients, we suggest hat ARB therapy, in addition to reduc- 
ing BP, has the potential to suppress CAM expression and to improve endothe- 
lial dysfunction in hypertension. (Curr Ther Res Clin Exp. 2005;66:181-194) Copy- 
right © 2005 Excerpta Medica, Inc. 
Key words: soluble cell adhesion molecule, ambulatory blood pressure 
monitoring, systemic hypertension, angiotensin II-receptor blockers. 
INTRODUCTION 
Hypertension is one of the main risk factors for cardiovascular disease and ath- 
erosclerosis. The formation of atherosclerotic lesions and subsequent develop- 
ment of coronary heart disease (CHD) result from the activation and expression of 
cell adhesion molecules (CAMs). 1 Soluble CAMs (sCAMs), which lack cytoplasmic- 
and membrane-spanning domains, are present in circulation. 2 Little is known 
about cell-surface shedding and clearance of these molecules; however, their 
levels in serum and plasma can be readily determined, 2,3 making clinical inves- 
tigation possible. 3,4 
Because the expression of CAMs is tightly regulated, uncontrolled cell immi- 
gration is avoided. 5 Consequently, the levels of CAMs in circulation may reflect 
endothelial inflammation/activation. 6-8 
Previous studies have demonstrated that the soluble isoforms of intercellular 
adhesion molecule-1 (sICAM-1), vascular cell adhesion molecule-1 (sVCAM-1), 
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and E-selectin (sE-selectin) are present in the circulation and elevated in idiopath- 
ic pulmonary fibrosis, 9diabetes mellitus, 1° dyslipidemia, 6 acute ischemic erebral 
infarction, u CHD 12-14 and its risk factors (eg, obesity), and atherosclerosis. 14-19 
However, controversy exists as to whether individuals with hypertension 
without other risk factors for atherosclerosis have elevated levels of CAMs. 16,20-24 
Moreover, even in population-based studies, the relationships between CAMs 
and blood pressure (BP) are inconsistent) 9,25-27 
The aim of this study was to determine whether (1) levels of sCAMs 
(sE-selectin, slCAM-1, sVCAM-1, and von Willebrand factor [vWF]) are elevated 
in Taiwanese adults with uncomplicated essential hypertension without other 
risk factors; (2) CAM levels increase with severity (stage) of hypertension; and 
(3) monotherapy with the angiotensin II-receptor blocker (ARB) irbesartan 
modulates CAM expression in a subgroup of these patients. 
PATIENTS AND METHODS 
Study Participants 
Taiwanese patients aged >-18 years with uncomplicated essential hyperten- 
sion without other risk factors for atherosclerosis (eg, diabetes mellitus, dys- 
lipidemia, obesity) and healthy volunteers (normotensive control group) were 
enrolled in the study. All participants were recruited for this observational, 
controlled pilot study from the Hypertension Clinic, Department of Internal 
Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. The 
study was approved by the ethics committee at the hospital, and all eligible 
patients gave verbal informed consent. 
Hypertensive patients were enrolled after 2 clinical visits at which diastolic 
BP (DBP) was >95 mm Hg as measured using a mercury sphygmomanometer 
(REX, Tokyo, Japan). Patients with hypertension receiving antihypertensive 
agents were asked to discontinue medication for 2 weeks before entry. 
Normotensive subjects were eligible if they had no history of cardiac disease 
and had normal cardiac function, as assessed using cardiac ultrasonography 
(HP SONOS 5500 Image System, Hewlett-Packard Development Company, LP, 
Andover, Massachusetts). They were excluded if they were receiving medical 
therapy. 
Hypertensive individuals were excluded from the study if they had diabetes 
mellitus, stroke, elevated (>1.3 mg/dL) serum creatinine levels, or abnormal 
findings on resting electrocardiography. Additional exclusion criteria were seri- 
ous concomitant disease (eg, autoimmune disease), recent acute infection, or in- 
flammatory disease. Patients who were pregnant, possibly pregnant, or breast- 
feeding also were excluded. 
Laboratory Testing and Clinical Assessments 
On the morning of the study day, after a 12-hour overnight fast, all hyperten- 
sive patients and controls underwent thorough physical examination and fast- 
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ing blood chemistry analysis (urinalysis, blood urea nitrogen measurement, 
serum lipid profile, and plasma glucose and serum creatinine measurements). 
Blood samples were also collected by a laboratory technician for the determi- 
nation of CAM levels. Lipids and lipoproteins were determined using elec- 
trophoresis. Low-density lipoprotein cholesterol levels were calculated using 
the Friedewald formula. 28 Other examinations included chest radiography (pos- 
teroanterior view); electrocardiography; M-mode and 2-dimensional cardiac 
ultrasonography; and studies to exclude secondary hypertension, diabetes 
mellitus, and renal disease. 
To determine whether monotherapy with irbesartan modulates the expres- 
sion of these sCAMs in relation to systemic hypertension, a subset of patients 
with hypertension enrolled in the late stage of this project received open-label 
irbesartan monotherapy, 150 to 300 mg QD (depending on BP) for 8 weeks. In 
these patients, blood chemistry analysis and measurement of sCAMs were 
repeated after treatment. In patients receiving irbesartan monotherapy, the dose 
was titrated to a maximum of 300 mg QD regardless of whether target BP was 
achieved. 
Ambulatory Blood Pressure Monitoring 
BP was measured using 24-hour ambulatory BP monitoring (ABP1V0. On the 
morning of the study day, after blood sampling, each participant underwent 
ABPM (model 90207 sphygmomanometer, SpaceLabs Medical, Inc., Redmond, 
Washington). This portable device uses a standard cuff placed around the left 
upper arm and inflated at regular intervals (every 30 minutes between 6AM and 
6 PM and every hour between 6 PM and 6 AM). Systolic BP (SBP) and DBP were 
estimated using oscillometry. At the end of the 24-hour monitoring period, 
BP measurement and heart rates were downloaded to a microcomputer for fur- 
ther analysis. Recordings howing an inconsistent increase or decrease in SBP 
or DBP of >50 mm Hg without changes in heart rate or a calculated pulse pres- 
sure <10 mm Hg were excluded from the analysis. Hypertension was defined as 
sitting office SBP/DBP >140/>90 mm Hg and a mean 24-hour ambulatory BP 
___135/~85 mm Hg. 29 
Patients with prehypertension r stage I or II hypertension were enrolled. 
The staging of hypertension was classified using the criteria in The Seventh 
Report of the Joint National Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure, 3° as follows: prehypertension (SBP 
120-139 mm Hg or DBP 80-89 mm Hg), stage I hypertension (SBP 140-159 mm Hg 
or DBP 90-99 mm Hg), and stage II hypertension (SBP _>160 mm Hg or DBP 
>100 mm Hg). Mean 24-hour SBP <120 mm Hg or DBP <80 mm Hg was defined 
as normotensive. However, when a patient's SBP and DBP fell into different 
categories, the patient was classified in the higher category. In patients re- 
ceiving irbesartan monotherapy, irbesartan 150 mg/d was given. This close 
could be doubled at week 4 if DBP was >90 mm Hg or DBP was reduced by 
<10 mm Hg. 
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Measurement of Soluble Cell Adhesion Molecule Levels 
On the morning of the study day, blood samples for determining circulating 
levels of slCAM-1, sVCAM-1, sE-selectin, and vWF were collected after a 12-hour 
overnight fast with minimal venostasis. Plasma levels of sCAMs and sE-selectin 
were determined in duplicate using a monoclonal antibody-based enzyme- 
linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, Minnesota). 
Plasma vWF level was measured using the ELISA kit, which contained specific 
rabbit-human vWF antibodies. 
Statistical Analysis 
Between-group differences were analyzed using the Mann-Whitney U test. 
The differences between baseline and posttreatment values were analyzed 
using the Wilcoxon rank sum test. The correlation between 24-hour SBP/DBP 
and sCAMs was assessed using the Spearman rank correlation test. All values 
are reported as mean (SD). P < 0.05 was considered significant. All statistical 
analyses were performed using SPSS version 11.0 (SPSS Inc., Chicago, Illinois). 
RESULTS 
Study Population 
Eighty-five individuals were enrolled in the study; the data from 7 of these 
were excluded from the study--4 because of diabetes mellitus and 3 because 
serum creatinine level was >2.0 mg/dL. Thus, 78 individuals completed the 
study, including 61 patients (78.2%) with uncomplicated essential hypertension 
(33 men, 28 women; mean [SD] age, 51 [12] years) and 17 normotensive controls 
(21.8%) (11 men, 6 women; mean [SD] age, 52 [11] years) (Table 1). 
Ambulatory Blood Pressure 
Mean (SD) 24-hour SBP/DBP values were significantly higher in the hyperten- 
sive patients compared with normotensive controls (143 [15]/91 [10] mm Hg vs 
119 [8]/75 [7] mm Hg; both, P < 0.001). No significant between-group differences 
in fasting plasma glucose level or in serum levels of creatinine, cholesterol, or 
triglycerides were observed (Table 1). 
Of the 61 hypertensive patients, 20 (32.8%) were classified as having prehy- 
pertension (mean [SD] 24-hour SBP/DBP, 131 [5]/83 [6] mm Hg); 27 (44.3%), as 
stage I hypertension (142 [10]/96 [6] mm Hg); and 14 (23.0%), as stage II hyper- 
tension (162 [13]/103 [10] mm Hg). 
Soluble Cell Adhesion Molecule Levels 
Compared with the normotensive group, the hypertensive group had sig- 
nificantly higher levels of sICAM-1 (318 [118] vs 236 [61] ng/mL; P = 0.009) 
(Table If). There were no significant differences in sVCAM-1, sE-selectin, or 
vWF levels between patients classified in any hypertensive stage and the 
control group. 
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Table I. Baseline demographic and clinical characteristics of the study population 
(N = 78). 
Hypertensive Control 
Characteristic (n = 61) (n = 1 7) 
Age, y 
Mean (SD) 51 (12) 52 (11) 
Sex, no. (%) 
Male 33 (54) 11 (65) 
Female 28 (46) 6 (35) 
24-h Ambulatory BP, mean (SD), mm Hg 
SBP 143 (15)* 119 (8) 
DBP 91 (10)* 75 (7) 
Hypertension stage 
Prehypertension 
No. of patients (%) 20 (33) - 
SBP, mean (SD), mm Hg 1 31 (5) - 
DBP, mean (SD), mm Hg 83 (6) - 
Stage I 
No. of patients (%) 27 (44) - 
SBP, mean (SD), mm Hg 142 (10) - 
DBP, mean (SD), mm Hg 96 (6) - 
Stage II 
No. of patients (%) 14 (23) - 
SBP, mean (SD), mm Hg 162 (1 3) - 
DBP, mean (SD), mm Hg 103 (10) - 
Biochemistry, mean (SD), mg/dL 
FPG 97 (1 7) 101 (11) 
Creatinine 1.0 (0.3) 0.9 (0.2) 
TC 201 (35) 193 (38) 
LDL-C 134 (29) 1 31 (38) 
VLDL-C 32 (19) 26 (14) 
HDL-C 41 (10) 41 (10) 
TO 116 (55) 107 (60) 
BP = blood pressure; SBP = systolic blood pressure; DBP = diastolic blood pressure; FPG = fasting plas- 
ma glucose; TC = total cholesterol; LDL-C -- low-density lipoprotein cholesterol; VLDL-C = very low- 
density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; TG = triglycerides. 
*P < 0.001 versus control group. 
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Table II. Baseline mean (SD) plasma cell adhesion molecule levels in the study popu- 
lation (N = 78). 
Hypertensive Control 
Component (n -- 61) (n = 17) 
slCAM-1, ng/mL 318 (118)* 236 (61) 
sVCAM-1, ng/mL 565 (243) 523 (1 30) 
sE-selectin, ng/mL 51.0 (23.7) 38.7 (16.2) 
vWF, mU/mL 790 (182) 770 (238) 
sICAM-1 = soluble intercellular dhesion molecule-I; sVCAM-1 = soluble vascular cell adhesion molecule-1; 
sE-selectin = soluble E-selectin; vWF -- von Willebrand factor. 
*P = 0.009 versus control group. 
Compared with normotensive controls, the patients classified as prehyper- 
tensive had significantly higher levels of sICAM-1 (P = 0.03); however, no signif- 
icant differences in sICAM-1 level were found between prehypertensive patients 
and those with stage I and II hypertension (Figure 1A). 
The levels of sE-selectin were significantly higher in patients with stage I
hypertension compared with the prehypertensive group (P = 0.01), but there 
were no differences in sE-selectin levels between patients with stage I and II 
hypertension (Figure 1B). No differences in levels of sVCAM-1 and vWF were 
observed between groups by hypertension stage. 
Correlation Analysis 
With hypertensive patients and normotensive controls considered togeth- 
er as a group, the pooled scatter plots of slCAM-1 and sE-selectin versus mean 
24-hour SBP and DBP are shown in Figure 2. By regression analysis, both sICAM-1 
(r = 0.295 and P = 0.009; Figure 2A) and sE-selectin (r = 0.333 and P = 0.003; 
Figure 2B) showed positive correlations with mean 24-hour SBP. Although no 
correlation between sICAM-1 versus mean 24-hour DBP was noted (Figure 2C), 
there was a positive correlation between sE-selectin (r = 0.291, P = 0.010) and 
mean 24-hour DBP (Figure 21)). In contrast, sVCAM-1 and vWF were not corre- 
lated with either mean 24-hour SBP or DBP (data not shown). 
Effects of Angiotensin Receptor Blockade Therapy 
In the 18 patients who received 8 weeks of monotherapy with the ARB ir- 
besartan, the mean (SD) dose was 243 (63) mg. The mean 24-hour SBP/DBP 
decreased significantly from pretreatment to week 8 (142 [14]/88 [9] vs 125 [1 ]/ 
78 [8] mm Hg; both, P < 0.001). sE-selectin levels also decreased significantly 
(55.3 [29.0] vs 44.2 [28.1] ng/mL; P = 0.006). No significant changes in the levels 
of sICAM-1, sVCAM-1, or vWF were seen in the irbesartan-treated patients 
(Table III). 
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Figure 1. Comparison of plasma levels of (A) soluble intercellular adhesion molecule-1 
(slCAM-1) and (B) soluble E-selectin (sE-selectin) between each stage of 
hypertension and with normotensive controls. *P = 0.03 versus normotensive 
controls; ?P = 0.01 versus prehypertension group. 
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Table III. Mean (SD) and ambulatory blood pressure (BP) and plasma cell adhesion 
molecule levels before and after irbesartan monotherapy for hypertension.* 
Irbesartan (n = 18) 
Control 
Parameter Before After (n = 1 7) 
24-h Ambulatory BP, mm Hg 
SBP 142 (14) 125 (11 )t 119 (8) 
DBP 88 (9) 78 (8) t 75 (7) 
slCAM-I, ng/mL 298 (I 33) 275 (86) 236 (61) 
sVCAM-I, ng/mL 504 (I 62) 484 (124) 523 (I 30) 
sE-selectin, ng/mL .55.3 (29.0) 44.2 (28.1)* 38.7 (16.2) 
vWF, mU/mL 81 3 (190) 797 (177) 770 (238) 
SBP -- systolic BP; DBP = diastolic BP; slCAM-1 = soluble intercellular adhesion molecule-I; sVCAM-1 = 
soluble vascular cell adhesion molecule-I; sF-selectin = soluble E-selectin; vWF =von Willebrand factor. 
*No significant between-group differences were found. 
tp < 0.001 versus before therapy. 
~P = 0.006 versus before therapy. 
DISCUSSION 
Based on the results of this study, we suggest that even mildly elevated BP (pre- 
hypertension and stage I hypertension) is sufficient o activate CAM expres- 
sion, particularly slCAM-1 and sE-selectin. An increase in severity (stage) of 
hypertension was not associated with a change in the expression of the 2 CAMs. 
This observation is, at least in part, consistent with those in the study by 
Preston et al, 31 in which the strong positive correlation between slCAM-1, 
sVCAM-1, and vWF levels versus BP in patients with normotension or mild 
hypertension was not found in patients with severe hypertension (mean 
SBP/DBP, 195 [26]/127 [7] mm Hg). 
The mechanisms by which systemic hypertension leads to an increase in lev- 
els of particular CAMs is not fully understood. Hemodynamics (eg, shear stress, 
mechanical stress, stretching, and humoral changes) play an important role in 
endothelial function. 32 Clinical interest regarding sCAMs is increasing 9 due to 
their association with atherosclerosis 6,11-13 and their possible use as biochemi- 
cal markers of atherogenic risk. 
Systolic hypertension is more likely to induce hypertension-related en othe- 
lial damage and dysfunction than is diastolic hypertension. 33 An association 
between SBP and slCAM-1 and sE-selectin, and DBP and sE-selectin was ob- 
served in our study. These relationships may help to explain why SBP is a bet- 
ter predictor of cardiovascular events than DBP, particularly in elderly (age, 
>65 years) hypertensive patients. 
We observed a linear association between sE-selectin and SBP and DBP. This 
finding is in agreement with some 3,19,20 but not all previous tudies. 21,23,32 These 
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discrepancies may reflect he different characteristics of different ethnic groups. 
The levels of sE-selectin might be related to vascular damage and might be a 
marker for endothelial damage. 34 
Two months of open-label irbesartan monotherapy in a subgroup of 18 patients 
resulted in a decrease in sE-selectin level and BP. It is still unclear whether ARB 
therapy modulates the expression of sCAMs in hypertensive individuals and 
its mechanism. In addition to their antihypertensive effect, the ARBs telmisartan 
and irbesartan also function as partial peroxisome-proliferator-activated 
receptor-gamma agonists. 35,36 In the present study, however, we did not find a cor- 
relation between reduced SBP and DBP and changes in sE-selectin level with irbe- 
sartan monotherapy, which might suggest hat the effect of ARBs on sE-selectin 
and/or CAM expression i  hypertension is independent oftheir BP-lowering effect. 
We suggest that ARB therapy, in addition to reducing BP, has the potential to sup- 
press CAM expression and improve endothelial dysfunction. 
This preliminary study had some limitations. Due to difficulty in achieving 
target BP with monotherapy, combination antihypertensive therapy (2 or 3 
drugs) was needed in 43 hypertensive patients, which reduced the subgroup 
receiving irbesartan monotherapy to 18 patients. Because the CAM levels were 
not measured in these 43 patients, we could not compare them between differ- 
ent classes of antihypertensive agents. Additional limitations of our study in- 
cluded the relatively small number of normotensive subjects compared with 
the number of hypertensive patients and the short treatment period, which lim- 
ited the power of our study to detect changes in CAM levels after therapy. 
A long-term, randomized, blinded, placebo-controlled follow-up ARB study is 
warranted. 
CONCLUSION 
Based on the results of this observational, controlled pilot study in Taiwanese 
patients, we suggest hat ARB therapy, in addition to reducing BP, has the 
potential to suppress CAM expression and improve endothelial dysfunction in 
hypertension. 
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